APA (7th ed.) Citation

Soung, J., Cather, J., Gooderham, M., Ryan, C., Somani, N., Feely, M., . . . Armstrong, A. W. (2023). Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q). JEADV Clinical Practice, 2(2), 282. https://doi.org/10.1002/jvc2.126

Chicago Style (17th ed.) Citation

Soung, Jennifer, et al. "Improvement in General Touch Avoidance in Patients with Moderate‐to‐severe Genital Psoriasis Treated with Ixekizumab During a 52‐week, Randomized, Phase 3 Clinical Trial (IXORA‐Q)." JEADV Clinical Practice 2, no. 2 (2023): 282. https://doi.org/10.1002/jvc2.126.

MLA (9th ed.) Citation

Soung, Jennifer, et al. "Improvement in General Touch Avoidance in Patients with Moderate‐to‐severe Genital Psoriasis Treated with Ixekizumab During a 52‐week, Randomized, Phase 3 Clinical Trial (IXORA‐Q)." JEADV Clinical Practice, vol. 2, no. 2, 2023, p. 282, https://doi.org/10.1002/jvc2.126.